Dimension Announces Positive Preclinical Results for an Adeno-Associated Virus Delivery of Factor VIII in Hemophilia Treatment

Dimension Therapeutics recently revealed positive preclinical results from a novel adeno-associated virus (AAV) that delivers Factor VIII as a therapeutic approach for hemophilia A patients. The results were presented in a poster, titled “Optimized AAV-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice and Cynomolgus Macaques” at the 19th American Society of Gene and Cell Therapy (ASGCT)…